BR112013031040A2 - multímero insulina-polímero não peptidil e método para a produção dos mesmos - Google Patents

multímero insulina-polímero não peptidil e método para a produção dos mesmos

Info

Publication number
BR112013031040A2
BR112013031040A2 BR112013031040A BR112013031040A BR112013031040A2 BR 112013031040 A2 BR112013031040 A2 BR 112013031040A2 BR 112013031040 A BR112013031040 A BR 112013031040A BR 112013031040 A BR112013031040 A BR 112013031040A BR 112013031040 A2 BR112013031040 A2 BR 112013031040A2
Authority
BR
Brazil
Prior art keywords
insulin
multimer
peptidyl
polymer
producing same
Prior art date
Application number
BR112013031040A
Other languages
English (en)
Inventor
Dae Jin Kim
Myung Hyun Jang
Se Chang Kwon
Sung In Lim
Sung Youb Jung
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of BR112013031040A2 publication Critical patent/BR112013031040A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo da patente de invenção para: “multímero insulina-polímero não peptidil e método para a produção dos mesmos”. a presente invenção refere-se a um multímero insulina-polímero não peptidil compreendendo dois ou mais de um conjugado de insulina-polímero não peptidil preparado por meio de ligação de um polímero não peptidil e insulina através de uma ligação covalente, em que os conjugados são complexados com iões de cobalto para formar um multímero, um método e kit para a preparação do multímero, uma composição farmacêutica para a prevenção ou tratamento de diabetes compreendendo o multímero como ingrediente ativo e um método para a prevenção ou tratamento de diabetes por meio da administração da composição a um sujeito.
BR112013031040A 2011-06-02 2012-06-01 multímero insulina-polímero não peptidil e método para a produção dos mesmos BR112013031040A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110053487 2011-06-02
PCT/KR2012/004368 WO2012165916A2 (en) 2011-06-02 2012-06-01 Non-peptidyl polymer-insulin multimer and method for producing the same

Publications (1)

Publication Number Publication Date
BR112013031040A2 true BR112013031040A2 (pt) 2016-11-29

Family

ID=47260122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031040A BR112013031040A2 (pt) 2011-06-02 2012-06-01 multímero insulina-polímero não peptidil e método para a produção dos mesmos

Country Status (13)

Country Link
US (1) US9944688B2 (pt)
EP (1) EP2714095A4 (pt)
JP (1) JP6005732B2 (pt)
KR (1) KR101417934B1 (pt)
CN (2) CN107397953A (pt)
AR (1) AR086659A1 (pt)
AU (1) AU2012263099B2 (pt)
BR (1) BR112013031040A2 (pt)
CA (1) CA2837851A1 (pt)
RU (1) RU2606262C2 (pt)
SG (1) SG195192A1 (pt)
TW (1) TWI565714B (pt)
WO (1) WO2012165916A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899418C (en) * 2013-02-26 2022-05-03 Hanmi Pharm. Co., Ltd. Site-specific insulin conjugate
CN105820233B (zh) * 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
CN107436311B (zh) * 2016-05-25 2021-11-19 正大天晴药业集团股份有限公司 一种鉴别胰岛素单体或胰岛素多聚体的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1753779A2 (en) * 2004-05-19 2007-02-21 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP2626368B1 (en) * 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1812864A2 (en) 2004-10-07 2007-08-01 Emory University Multifunctional nanoparticles conjugates and their use
WO2006053906A1 (en) * 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
PL1907419T3 (pl) * 2005-07-08 2011-08-31 Biocon Ltd Wytwarzanie koniugatów insuliny
EP2240782A2 (en) 2008-02-04 2010-10-20 Ulive Enterprises Limited Nanoparticle conjugates
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
NZ618800A (en) 2015-08-28
TW201302784A (zh) 2013-01-16
CN107397953A (zh) 2017-11-28
US9944688B2 (en) 2018-04-17
US20140107023A1 (en) 2014-04-17
KR101417934B1 (ko) 2014-07-10
KR20120135122A (ko) 2012-12-12
EP2714095A4 (en) 2015-04-08
AU2012263099A1 (en) 2014-01-16
CN103747806A (zh) 2014-04-23
CA2837851A1 (en) 2012-12-06
JP6005732B2 (ja) 2016-10-12
WO2012165916A3 (en) 2013-03-28
JP2014516985A (ja) 2014-07-17
EP2714095A2 (en) 2014-04-09
TWI565714B (zh) 2017-01-11
AR086659A1 (es) 2014-01-15
AU2012263099B2 (en) 2017-06-29
RU2606262C2 (ru) 2017-01-10
WO2012165916A2 (en) 2012-12-06
RU2013152687A (ru) 2015-07-20
SG195192A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
MX2022003458A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
UA106878C2 (uk) Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112012028766A2 (pt) processo para a preparação de complexos de insulina e zinco
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112013000282A2 (pt) derivados do ácido (2-arilóxi-acetilamino)-fenil-propiônico, método para produzir o mesmo e a utilização dos mesmos como produtos farmacêuticos
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
BR112012015977A2 (pt) composto derivado de poli (ácido lático), método para preparar o composto derivado de poli (ácido lático), complexo do composto de derivado de poli (ácido lático), composição de liberação prolongada de droga, e, método para preparar a composição de liberação prolongada de droga
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112014010818A2 (pt) método para preparar complexo de polipeptídeo fisiologicamente ativo
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/62 (2006.01), A61K 38/28 (2006.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.